BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 38601181)

  • 1. Assessment and prognostic significance of a serum cytokine panel in diffuse large B‑cell lymphoma.
    Xie S; Zhu L; Wang L; Wang S; Tong X; Ni W
    Oncol Lett; 2024 May; 27(5):237. PubMed ID: 38601181
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytokine profiles in patients with newly diagnosed diffuse large B-cell lymphoma: IL-6 and IL-10 levels are associated with adverse clinical features and poor outcomes.
    Bao C; Gu J; Huang X; You L; Zhou Z; Jin J
    Cytokine; 2023 Sep; 169():156289. PubMed ID: 37453327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Expression and Prognostic Value of Cytokines in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma].
    Man Y; Ge CQ; Li ZZ; Yang TH; Wang YJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Aug; 31(4):1050-1055. PubMed ID: 37551476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Derangements of immunological proteins in HIV-associated diffuse large B-cell lymphoma: the frequency and prognostic impact.
    Vaughan J; Patel M; Suchard M; Gededzha M; Ranchod H; Howard W; Snyman T; Wiggill T
    Front Cell Infect Microbiol; 2024; 14():1340096. PubMed ID: 38633747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High serum levels of soluble interleukin-2 receptor (sIL2-R), interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF) are associated with adverse clinical features and predict poor outcome in diffuse large B-cell lymphoma.
    Dlouhy I; Filella X; Rovira J; Magnano L; Rivas-Delgado A; Baumann T; Martínez-Trillos A; Balagué O; Martínez A; González-Farre B; Karube K; Gine E; Delgado J; Campo E; López-Guillermo A
    Leuk Res; 2017 Aug; 59():20-25. PubMed ID: 28544905
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Expression and Clinical Significance of Cytokines and Lymphocyte Subsets in Patients with Diffuse Large B-Cell Lymphoma].
    Xie Y; Bao HY; Shi XF; Wang JN; Han X; Meng QQ; Jiang SY; Zhang L; Zhang LB; Chen WR; Zou XD
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Auguest; 31(4):1061-1068. PubMed ID: 37551478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma TNF-alpha and IL-10 level-based prognostic model predicts outcome of patients with diffuse large B-Cell lymphoma in different risk groups defined by the International Prognostic Index.
    Lech-Maranda E; Bienvenu J; Broussais-Guillaumot F; Warzocha K; Michallet AS; Robak T; Coiffier B; Salles G
    Arch Immunol Ther Exp (Warsz); 2010 Apr; 58(2):131-41. PubMed ID: 20191326
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical characteristics and outcomes of patients with diffuse large B cell lymphoma treated with R-CHOP-like or CHOP-like regimens: an 8-year experience from a single center.
    Huang H; Fan L; Fu D; Lin Q; Shen J
    Ann Palliat Med; 2020 Jul; 9(4):1442-1452. PubMed ID: 32648457
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression and Prognostic Value of PIK3CA, VEGF, IL-8, IL-10, and RIP2 in Diffuse Large B-Cell Lymphoma.
    Shen N; Yu Y; Zhang R; Guo Y; Liu M; Tan M; Liu J; Bai J; Li L; Liu K; Wang R; He J
    Int J Clin Pract; 2022; 2022():2637581. PubMed ID: 36567775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. C-reactive protein level is a prognostic indicator for survival and improves the predictive ability of the R-IPI score in diffuse large B-cell lymphoma patients.
    Troppan KT; Schlick K; Deutsch A; Melchardt T; Egle A; Stojakovic T; Beham-Schmid C; Weiss L; Neureiter D; Wenzl K; Greil R; Neumeister P; Pichler M
    Br J Cancer; 2014 Jul; 111(1):55-60. PubMed ID: 24874478
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pretreatment circulating serum cytokines associated with follicular and diffuse large B-cell lymphoma: a clinic-based case-control study.
    Charbonneau B; Maurer MJ; Ansell SM; Slager SL; Fredericksen ZS; Ziesmer SC; Macon WR; Habermann TM; Witzig TE; Link BK; Cerhan JR; Novak AJ
    Cytokine; 2012 Dec; 60(3):882-9. PubMed ID: 23010502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of serum aspartic transaminase in diffuse large B-cell lymphoma.
    Lu TX; Wu S; Cai DY; Hong TT; Zhang Y; Gao HQ; Hua HY; Wu XH
    BMC Cancer; 2019 Jun; 19(1):553. PubMed ID: 31176361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum levels of inflammatory cytokines at diagnosis correlate to the bcl-6 and CD10 defined germinal centre (GC) phenotype and bcl-2 expression in patients with diffuse large B-cell lymphoma.
    Pedersen LM; Jürgensen GW; Johnsen HE
    Br J Haematol; 2005 Mar; 128(6):813-9. PubMed ID: 15755285
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The significance of pretreatment anemia in the era of R-IPI and NCCN-IPI prognostic risk assessment tools: a dual-center study in diffuse large B-cell lymphoma patients.
    Troppan KT; Melchardt T; Deutsch A; Schlick K; Stojakovic T; Bullock MD; Reitz D; Beham-Schmid C; Weiss L; Neureiter D; Wenzl K; Greil R; Neumeister P; Egle A; Pichler M
    Eur J Haematol; 2015 Dec; 95(6):538-44. PubMed ID: 25677782
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatitis B Surface Antigen Positivity Is an Independent Unfavorable Prognostic Factor in Diffuse Large B-Cell Lymphoma in the Rituximab Era.
    Cheng CL; Huang SC; Chen JH; Wei CH; Fang WQ; Su TH; Yuan CT; Liu JH; Chuang MK; Tien HF
    Oncologist; 2020 Sep; 25(9):793-802. PubMed ID: 32275807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The gut microbiota correlate with the disease characteristics and immune status of patients with untreated diffuse large B-cell lymphoma.
    Lin Z; Mao D; Jin C; Wang J; Lai Y; Zhang Y; Zhou M; Ge Q; Zhang P; Sun Y; Xu K; Wang Y; Zhu H; Lai B; Wu H; Mu Q; Ouyang G; Sheng L
    Front Immunol; 2023; 14():1105293. PubMed ID: 36891300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinicopathological Characteristics of Patients with Intestinal Diffuse Large B-Cell Lymphoma].
    Mou K; Shi ML; Yang FL; Wu XF; Guo XQ; Qi JD
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Apr; 29(2):508-514. PubMed ID: 33812422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic nomogram incorporating inflammatory cytokines for overall survival in patients with aggressive non-Hodgkin's lymphoma.
    Zhong H; Chen J; Cheng S; Chen S; Shen R; Shi Q; Xu P; Huang H; Zhang M; Wang L; Wu D; Zhao W
    EBioMedicine; 2019 Mar; 41():167-174. PubMed ID: 30827933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Presence of a high-grade component in gastric mucosa-associated lymphoid tissue (MALT) lymphoma is not associated with an adverse prognosis.
    Ang MK; Hee SW; Quek R; Yap SP; Loong S; Tan L; Tao M; Lim ST
    Ann Hematol; 2009 May; 88(5):417-24. PubMed ID: 18777110
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TNF-α expression in tumor cells as a novel prognostic marker for diffuse large B-cell lymphoma, not otherwise specified.
    Nakayama S; Yokote T; Hirata Y; Akioka T; Miyoshi T; Hiraoka N; Iwaki K; Takayama A; Nishiwaki U; Masuda Y; Nishimura Y; Tsuji M; Hanafusa T
    Am J Surg Pathol; 2014 Feb; 38(2):228-34. PubMed ID: 24145654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.